BIO-TECHNE Corp vs Vanguard Total Stock Market Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Vanguard Total Stock Market Index Fund ETF trades at $380.91 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 202.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| TECH | VTI | |
|---|---|---|
Market Cap | $11.36B | $2.30T |
Volume | 5,390,331 | 2,982,924 |
Sector | Health | — |
52-Week High | $72.61 | $384.30 |
52-Week Low | $43.31 | $311.68 |
Typical Hold Time | 63 Days | 131 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
VTI trades at $381.03, down 0.39% on the day, with bullish technical signals from moving averages. The ETF maintains broad exposure to the entire U.S. equity market with over 3,500 holdings. Recent news highlights strong long-term performance potential, with $500 monthly investments since 2001 growing to approximately $876,000 according to The Motley Fool (2026-10-01).
VTI offers diversified U.S. stock market exposure with low expense ratios, making it suitable for long-term investors. Key risks include concentration in top holdings and market volatility. Analyst sentiment remains positive for buy-and-hold strategies, though current RSI levels suggest potential near-term consolidation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →